SCHOLAR ROCK INC is a biotechnology company focused on Metabolic, Oncology. Key products include ISEMBYLD.
SCHOLAR ROCK INC's Key Drugs
SCHOLAR ROCK INC's core commercial portfolio centers on ISEMBYLD, spanning Metabolic and Oncology — its most strategically important drugs approved in the last 15 years.
SCHOLAR ROCK INC's Recent FDA Approvals
SCHOLAR ROCK INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SCHOLAR ROCK INC's Therapeutic Areas
SCHOLAR ROCK INC's approved drugs and pipeline span 2 therapeutic areas, led by Metabolic and Oncology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SCHOLAR ROCK INC's Top Competitors
SCHOLAR ROCK INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SCHOLAR ROCK INC Pipeline Snapshot
SCHOLAR ROCK INC has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ISEMBYLD leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/2 completed
- • Speed: 46 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2026-09-11
- Latest
- 2026-09-11
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges